Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 1/20 | 0.50 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | PRKCH | P24723 | 6/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.34 |
| ▸ | LATS1 | O95835 | 2/20 | 0.34 |
| ▸ | PRKCB | P05771 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17700270 | 0.85 | GOT1 (0.48) | GOT1NUDT1P2RX7FFAR2 | |
| SCHEMBL6702893 | 0.76 | CXCR4 (0.52) | — | |
| SCHEMBL30864862 | 0.75 | — | — | |
| SCHEMBL18077511 | 0.75 | — | — | |
| SCHEMBL28148590 | 0.74 | GOT1 (0.39) | GOT1 | |
| SCHEMBL8170897 | 0.72 | GOT1 (0.55) | GOT1P2RX7PRKCHPRKCEROCK2 | |
| SCHEMBL5940546 | 0.72 | GOT1 (0.50) | GOT1P2RX7FFAR2 | |
| SCHEMBL22654910 | 0.71 | MAPT (0.50) | IL1BNUDT1PRKCHPRKCQPRKCE | |
| SCHEMBL12212573 | 0.71 | IL1B (0.45) | IL1BNUDT1PRKCHPRKCQPRKCE | |
| SCHEMBL17036640 | 0.71 | GOT1 (0.54) | GOT1P2RX7FFAR2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | GOT1 338/4885IL1B 2071/4885NUDT1 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.